Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 5/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | CCND1 | P24385 | 2/20 | 0.35 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25444116 | 0.88 | KDM5A (0.36) | KDM5ACDK9CCNT1CDK4CCND1 | |
| SCHEMBL25444136 | 0.88 | KDM5A (0.36) | KDM5ACDK9CCNT1CDK4CCND1 | |
| SCHEMBL23081198 | 0.88 | KDM5A (0.36) | KDM5ACDK9CCNT1CDK4CCND1 | |
| SCHEMBL23081357 | 0.82 | EPHX1 (0.37) | KDM5ACDK9CCNT1CDK4CCND1 | |
| SCHEMBL23119126 | 0.74 | MME (0.36) | CDK9MMEHPGDEPHX1 | |
| SCHEMBL23081202 | 0.73 | EPHX1 (0.36) | CDK9CCNT1CDK4CCND1CCNA2 | |
| SCHEMBL14748226 | 0.73 | EPHX1 (0.54) | HPGDEPHX1ALDH1A1 | |
| SCHEMBL14652117 | 0.72 | KDM5A (0.38) | KDM5AMMEHPGDBTK | |
| SCHEMBL23119123 | 0.71 | CDK9 (0.35) | CDK9MMEHPGDEPHX1 | |
| SCHEMBL21984724 | 0.69 | EPHX1 (0.48) | HPGDEPHX1ALDH1A1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144528-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK3, CDK9 | KDM5A 462/4885CDK9 3/4885CCNT1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.